Trials / Completed
CompletedNCT02501603
Afatinib, Paclitaxel, 2nd Line, Advanced Gastric Cancer
An Open-label, Multicenter Phase II Study of Afatinib Plus Weekly Taxol as Second Line Treatment for Advanced/Recurrent Gastric and Gastroesophageal Junction Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 72 (estimated)
- Sponsor
- Yonsei University · Academic / Other
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
For the gastric cancer, paclitaxel is recommended as salvage standard treatment. Afatinib is a novel, potent, small ErbB family blocker that covalently binds and irreversibly blocks signaling through activated EGFR, HER2 and ErbB4 receptors, as well as the transphosphorylation of ErbB3. The investigators suggest a randomized phase II trial of afatinib plus weekly taxol(paclitaxel) for previously treated EGFR positive gastric cancer patients. The aim of current trial is to evaluate the antitumor efficacy of afatinib for target enriched patients in gastric cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | afatinib | Afatinib 40mg daily oral administration |
| DRUG | paclitaxel | Paclitaxel 80mg/m2 IV weekly (day 1,8,15) |
Timeline
- Start date
- 2016-07-01
- Primary completion
- 2021-12-31
- Completion
- 2022-12-20
- First posted
- 2015-07-17
- Last updated
- 2023-01-27
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02501603. Inclusion in this directory is not an endorsement.